NASDAQ:PALI Palisade Bio (PALI) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free PALI Stock Alerts $6.71 -0.23 (-3.31%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$6.68▼$6.9050-Day Range$4.07▼$8.4652-Week Range$3.82▼$36.60Volume12,654 shsAverage Volume3.44 million shsMarket Capitalization$6.31 millionP/E RatioN/ADividend YieldN/APrice Target$131.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get Palisade Bio alerts: Email Address Palisade Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,856.0% Upside$131.25 Price TargetShort InterestBearish21.34% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.22Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.59 out of 5 stars 3.5 Analyst's Opinion Consensus RatingPalisade Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragePalisade Bio has only been the subject of 1 research reports in the past 90 days.Read more about Palisade Bio's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted21.34% of the float of Palisade Bio has been sold short.Short Interest Ratio / Days to CoverPalisade Bio has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Palisade Bio has recently increased by 417.39%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPalisade Bio does not currently pay a dividend.Dividend GrowthPalisade Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PALI. Previous Next 2.9 News and Social Media Coverage News SentimentPalisade Bio has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Palisade Bio this week, compared to 2 articles on an average week.Search Interest8 people have searched for PALI on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.MarketBeat Follows6 people have added Palisade Bio to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Palisade Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.24% of the stock of Palisade Bio is held by insiders.Percentage Held by InstitutionsOnly 11.79% of the stock of Palisade Bio is held by institutions.Read more about Palisade Bio's insider trading history. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Palisade Bio is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Palisade Bio is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPalisade Bio has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Manward PressShocking: One AI startup's revenue could surge 4,735%Shocking: One AI Startup's Revenue Could Surge 4,735% While Nvidia gets all the attention, one small AI startup is quietly positioning itself to be the biggest winner.Click here to discover the AI chip company About Palisade Bio Stock (NASDAQ:PALI)Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults. It has a license agreement with the Regents of the University of California; and co-development and distribution agreement with Newsoara Biopharma Co., Ltd. Palisade Bio, Inc. is based in Carlsbad, California.Read More PALI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PALI Stock News HeadlinesMay 7, 2024 | globenewswire.comPalisade Bio Appoints Margery Fischbein to its Board of DirectorsMay 7, 2024 | globenewswire.comPalisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq RulesMay 12, 2024 | Banyan Hill Publishing (Ad)READ THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”May 3, 2024 | americanbankingnews.comMaxim Group Reiterates "Buy" Rating for Palisade Bio (NASDAQ:PALI)May 2, 2024 | globenewswire.comPalisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq RulesMay 1, 2024 | msn.comMarijuana reclassified federally in major win for the legal cannabis industryMay 1, 2024 | msn.comPalisade Bio stock rallies 50% premarket on colitis drug updateMay 1, 2024 | finance.yahoo.comPalisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)May 12, 2024 | Banyan Hill Publishing (Ad)READ THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”May 1, 2024 | globenewswire.comPalisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)April 23, 2024 | msn.comPalisade Bio, Strand Life Sciences team up on colitis drug researchApril 23, 2024 | msn.comWhy Palisade Bio Stock Is Up TodayApril 23, 2024 | finance.yahoo.comPalisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine ApproachApril 23, 2024 | globenewswire.comPalisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine ApproachApril 19, 2024 | benzinga.comLooking Into Palisade Bio's Recent Short InterestApril 17, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE) and Palisade Bio (PALI)April 17, 2024 | msn.comHow Apple Car Key Works (and Why It Still Hasn’t Caught On)April 16, 2024 | msn.comPalisade Bio stock rallies nearly 100% on colitis drug analysisApril 16, 2024 | marketwatch.comPalisade Bio Shares Surge 80% After Lab Study Results for Ulcerative Colitis TreatmentApril 16, 2024 | msn.comWhy Palisade Bio Stock Is Soaring TodayApril 16, 2024 | investorplace.comWhy Is Palisade Bio (PALI) Stock Up 57% Today?April 16, 2024 | finance.yahoo.comPalisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ StoolApril 16, 2024 | globenewswire.comPalisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients' StoolApril 12, 2024 | uk.investing.comPalisade Bio advances ulcerative colitis treatment to Phase 1 studyApril 11, 2024 | globenewswire.comPalisade Bio to Participate in the Virtual Investor Lunch Break EventApril 10, 2024 | msn.comPalisade Bio stock slides 8% amid colitis drug presentationApril 10, 2024 | finance.yahoo.comPalisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™See More Headlines Receive PALI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Palisade Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/26/2024Today5/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:PALI CUSIPN/A CIK1357459 Webwww.palisadebio.com Phone(858) 704-4900FaxN/AEmployees9Year FoundedN/APrice Target and Rating Average Stock Price Target$131.25 High Stock Price Target$240.00 Low Stock Price Target$22.50 Potential Upside/Downside+1,856.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($27.1364) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,300,000.00 Net MarginsN/A Pretax Margin-4,920.00% Return on Equity-89.68% Return on Assets-76.18% Debt Debt-to-Equity RatioN/A Current Ratio5.15 Quick Ratio5.15 Sales & Book Value Annual Sales$250,000.00 Price / Sales25.23 Cash FlowN/A Price / Cash FlowN/A Book Value$18.29 per share Price / Book0.37Miscellaneous Outstanding Shares940,000Free Float917,000Market Cap$6.31 million OptionableNot Optionable Beta1.25 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. J. D. Finley (Age 66)CEO, CFO & Director Comp: $791.33kDr. Mitchell Lawrence Jones M.D. (Age 46)Ph.D., COO & Chief Medical Officer Comp: $635kMr. Ryker WillieSenior VP of Finance & Corporate ControllerKey CompetitorsCreative Medical TechnologyNASDAQ:CELZTitan PharmaceuticalsNASDAQ:TTNPNanoString TechnologiesNASDAQ:NSTGQFresh Tracks TherapeuticsNASDAQ:FRTXInhibikase TherapeuticsNYSE:IKTView All CompetitorsInsidersDonald Allen WilliamsBought 666 shares on 1/31/2024Total: $5,994.00 ($9.00/share)John David FinleyBought 1,000 shares on 9/27/2023Total: $8,100.00 ($8.10/share)Donald Allen WilliamsBought 1,333 shares on 9/27/2023Total: $10,797.30 ($8.10/share)Robert J. TrenschelSold 20 sharesTotal: $192.00 ($9.60/share)John David FinleyBought 1,000 shares on 9/13/2023Total: $9,900.00 ($9.90/share)View All Insider Transactions PALI Stock Analysis - Frequently Asked Questions Should I buy or sell Palisade Bio stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Palisade Bio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PALI shares. View PALI analyst ratings or view top-rated stocks. What is Palisade Bio's stock price target for 2024? 1 Wall Street analysts have issued twelve-month target prices for Palisade Bio's stock. Their PALI share price targets range from $22.50 to $240.00. On average, they predict the company's stock price to reach $131.25 in the next year. This suggests a possible upside of 1,856.0% from the stock's current price. View analysts price targets for PALI or view top-rated stocks among Wall Street analysts. How have PALI shares performed in 2024? Palisade Bio's stock was trading at $8.85 at the beginning of 2024. Since then, PALI stock has decreased by 24.2% and is now trading at $6.71. View the best growth stocks for 2024 here. How were Palisade Bio's earnings last quarter? Palisade Bio, Inc. (NASDAQ:PALI) issued its quarterly earnings results on Tuesday, March, 26th. The company reported ($3.75) earnings per share (EPS) for the quarter. When did Palisade Bio's stock split? Shares of Palisade Bio reverse split on the morning of Monday, April 8th 2024. The 1-15 reverse split was announced on Monday, April 8th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Palisade Bio? Shares of PALI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PALI) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsGold Set to EXPLODE!Gold Safe ExchangeShocking: One AI startup's revenue could surge 4,735%Manward Press[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palisade Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
